Cancer staging

About: Cancer staging is a research topic. Over the lifetime, 2242 publications have been published within this topic receiving 100014 citations. The topic is also known as: neoplasm staging.

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

Abstract: The American Joint Committee on Cancer and the International Union for Cancer Control update the tumor-node-metastasis (TNM) cancer staging system periodically. The most recent revision is the 7th edition, effective for cancers diagnosed on or after January 1, 2010. This editorial summarizes the background of the current revision and outlines the major issues revised. Most notable are the marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping. The future of cancer staging lies in the use of enhanced registry data standards to support personalization of cancer care through cancer outcome prediction models and nomograms.

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Abstract: The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a "population-based" to a more "personalized" approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as "what's new" in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93-99. © 2017 American Cancer Society.

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Abstract: PURPOSE: To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). MATERIALS AND METHODS: The prognostic factors analysis described in the companion publication (this issue), as well as evidence from the published literature, was used to assemble the tumor-node-metastasis criteria and stage grouping for the melanoma staging system. RESULTS: Major changes include (1) melanoma thickness and ulceration but not level of invasion to be used in the T category (except for T1 melanomas); (2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of clinically occult (ie, microscopic) versus clinically apparent (ie, macroscopic) nodal metastases to be used in the N category; (3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase to be used in the M category; (4) an upstaging of all patients with stage I, II, and III disease when a primary melanoma is ulcerated; (5) a merging of sa...

Manual for Staging of Cancer

Abstract: Part 1 General information on cancer staging and end-results reporting: purposes and principles of staging reporting of cancer survival and end results. Part 2 Staging of cancer at specific anatomic sites: lip and oral cavity, pharynx (including base of tongue, soft palate, and uvula) larynx maxillary sinus salivary glands (including parotid, submandibular, and sublingual), thyroid gland digestive system sites - oesophagus, stomach, small intestine, colon and rectum, anal canal, liver (including intrahepatic bile ducts), gallbladder, extrahepatic bile ducts, ampulla of vater, exocrine thorax - lung, pleural mesothelioma musculoskeletal sites - bone, soft tissue, carcinoma of the skin (excluding eyelid, vulva, and penis), melanoma of the skin (excluding eyelid), breast gynaecologic sites - cervix uteri, corpus uteri, ovary, vagina, vulva genitourinary sites - prostate, testis, penis, urinary bladder, kidney, renal pelvis and ureter, urethra ophthalmic tumours - carcinoma of the eyelid, melanoma of the eyelid, carcinoma of the conjunctiva, melanoma of the conjunctiva, melanoma of the uvea, retinoblastoma, sarcoma of the orbit, carcinoma of the lacrimal gland, brain lymphomas - Hodgkin's disease, non-Hodkin's lymphoma paediatric cancers - nephroblastoma (Wilms' tumour), neuroblastoma, soft-tissue sarcoma - paediatric. Part 3 Personnel of the american joint committee on cancer.